Supplementary material

IFN-γ enhances the therapeutic effect of MSCs on experimental renal fibrosis

Ryo Kanai, Ayumu Nakashima, Shigehiro Doi, Tomoe Kimura, Ken Yoshida, Satoshi Maeda, Naoki Ishiuchi, Yumi Yamada, Takeshi Ike, Toshiki Doi, Yukio Kato, and Takao Masaki

This file includes additional file 1 and 2.



Additional file 1. Effects of PTGES siRNA on the anti-fibrotic effects of IFN-γ-treated hMSCs *in vitro*. **a** After hMSCs were transfected with NC siRNA or PTGES siRNA, the cells were treated with IFN-γ, and then PTGES mRNA levels were evaluated by real-time PCR. PTGES mRNA levels were normalized to the level of 18S rRNA (n = 5 in each group). **b** After HK-2 cells were incubated with conditioned medium (CM) from

IFN-γ-treated hMSCs transfected with NC siRNA or PTGES siRNA for 24 hours, the cells were treated with TGF-β1. The figure and graph show western blot analysis of α-SMA in HK-2 cells. α-SMA protein levels were normalized to GAPDH levels (n = 3 in each group). Data are presented as the mean ± SD. *$p < 0.05$, **$p < 0.01$.



Additional file 2. Expression of PTGES mRNA in rMSCs. **a** PTGES mRNA levels in rMSCs treated with or without IFN-γ were evaluated by real-time PCR. PTGES mRNA

levels were normalized to 18S rRNA levels (n = 5 in each group). **b** After rMSCs were transfected with NC or PTGES siRNAs, rMSCs were treated with IFN-γ, and then PTGES mRNA levels were evaluated by real-time PCR. PTGES mRNA levels were normalized to the level of 18S rRNA (n = 5 in each group). Data are presented as the mean ± SD. $^{**}p < 0.01$.